Our website is in transition, if you are unable to locate a specific product please contact us.
News | Epredia
Close
Close Choose language
Select

You are leaving the full Epredia.com website. You will be redirected to the [language] site with limited information on our solutions for your laboratory. For more information please fill out the 'contact us' form and a sales representative will answer all of your questions.

Go Back
Continue

您即将离开 Epredia.com 完整网站。 您将被定向到转至中文网站,其中包含我们为您的实验室提供的解决方案的部分信息。如需了解更多信息,请填写“联系我们”表格,随后销售代表将回答您的所有问题。

后退
继续

News

Explore Recent News

Filters


Epredia and Aiforia announce partnership for global distribution of AI-powered pathology software

June 21, 2021

Epredia, a global leader in precision cancer diagnostics, and Aiforia, a medical software company providing Artificial Intelligence (AI) based solutions for image analysis in pathology, have announced today that they have entered into a commercial distribution agreement for Aiforia’s comprehensive portfolio of workflow enhancing solutions which enable pathologists to harness the power of deep learning AI for image analysis.

Under the terms of this agreement, Epredia has been appointed as a global distribution partner for Aiforia’s portfolio of preclinical and clinical pathology tools, including segment exclusivity for distribution in Japan, Germany, UK, Italy, Spain, Sweden, Norway, Denmark, Iceland, France and the USA. From Summer 2021, Epredia will begin to commercialize the Aiforia portfolio of AI solutions. These solutions will be available as part of Epredia’s comprehensive digital pathology portfolio that already features the best-in-class CE-marked 3DHistech P1000 WSI scanner*…Read more

* Regulatory requirements for the 3DHistech P1000 scanner and Aiforia's pathology solutions vary by country, please consult with your commercial partner to confirm the availability and approved use of the scanner and Aiforia's pathology solutions in your country.

Epredia invests in Aiforia, a software company providing AI-based solutions for clinical and preclinical image analysis in pathology

June 3, 2021

Aiforia, a software company providing AI-based solutions for clinical and preclinical image analysis in pathology, announced today the closing of the first €12.6M tranche of their Series B round. The funding round has the potential to reach €25.2M if investors exercise the optional second tranche

The funding round is led by Epredia’s UK entity, a subsidiary of PHC Holdings Corporation. Investors also include Aktia Nordic Micro Cap and existing shareholders. KPMG acted as a financial advisor to Aiforia in the successful Series B round…Read more

Epredia and Paige announce global commercial distribution agreement for digital pathology software

March 17, 2021

Epredia, a global leader in precision cancer diagnostics, and Paige, a global leader in AI-based diagnostic software in pathology, have announced today that they have entered into a commercial distribution agreement for Paige’s comprehensive portfolio of diagnostic software solutions.

Under the terms of this agreement, Epredia has been appointed as a global distribution partner of the entire Paige portfolio of imaging diagnostic solutions. In addition, Epredia will have exclusive distribution rights in Japan. In the second quarter of 2021, Epredia will begin to commercialize the Paige solutions alongside existing Epredia products in the United States and major European Countries, further strengthening its comprehensive digital pathology portfolio that already includes the best-in-class CE-marked 3DHISTECH P1000 scanner*…Read more

* Regulatory requirements for the 3DHistech P1000 scanner vary by country, please consult with your commercial partner to confirm the approved use of the scanner in your country.

Epredia and Lunaphore announce commercial agreement for exclusive distribution of LabSat® Research

June 15, 2020

Epredia, a global leader in precision cancer diagnostics and tissue diagnostics, and Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, have announced today that they have entered into a distribution agreement. This follows the announcement of a strategic investment in Lunaphore by PHC Holdings Corporation, the parent company of Epredia, which was announced on February 6, 2020.

Under the terms of this agreement, Epredia have been appointed the exclusive distributor of the LabSat® Research platform in the US, UK and Germany, where Epredia will start to distribute the product in July 2020, as well as Japan, where commercialization will begin in 2021…Read more